Lean body mass is commonly proposed for anesthesia maintenance drug dosing calculations. However, total body mass used with allometric scaling has been shown to be better for propofol in obese adults and children. Fat-free mass has also been used instead of lean body mass. Fat-free mass is essentially the same as lean body mass but excludes a small percentage of mass of lipids in cell membranes, CNS, and bone marrow. Normal fat mass is a size descriptor that partitions total body mass into fat-free mass and fat mass calculated from total body mass minus fat-free mass.
between the effects of obesity and those due to differences in size. 1 We will focus in this review primarily on maintenance dose rate and clearance, its pharmacokinetic determinant.
| CUR RENT D OSIN G REGIMENS FOR OBESE CHILDREN
There are few guidelines for drug dosing in obese children, 6, 7 and it is acknowledged as a dilemma. 8 A recent survey 9 highlighted the problem of drug dosing in the obese child. The authors identified 2 aspects that require greater attention from pediatric practitioners:
the identification of the obese child and the use of ideal body mass (IBM) for drug calculation in the obese child. Both involve effort from prescribers to go beyond simply considering TBM for dosing.
There remains uncertainty about the benefits of using IBM compared with using TBM, 10 which may explain the lack of enthusiasm to use size metrics other than TBM.
Propofol dosing in obese adults highlights the problem in anesthesia. Some common target-controlled infusion pumps deliver propofol using LBM for obese adults despite knowledge that propofol clearance is better calculated using TBM with allometric scaling. 11, 12 Dosing of midazolam in adolescents presenting for bariatric surgery remains problematic because of the lack of clear guidance for quantifying excess weight and using this to calculate the dose.
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| EMPIRICAL LINKS BETWEEN WE IGHT AND DOSE
Drugs are commonly dosed by weight. This is because the pharmacokinetic parameters (eg, CL, V) that determine dose are determined using size. Drug dose calculations are commonly made assuming a linear relationship between mass (TBM) and dose (Equation 1)
where a standard dose (Dose STD ) is considered appropriate for a person of standard weight (WT STD , eg, 70 kg). However, it is widely known that doses expressed as mg kg À1 are larger in children than in adults which brings into question this linear assumption and is a key reason why the linear approach is not a suitable general method for drug dosing in both children and adults. 8 Prediction using adult human clearance values with the linear per kg model leads to an under prediction of more than 10% at body weights less than 47 kg. This discrepancy increases as size decreases and approaches 50% around 10 kg (ie, 1-2 years of age). 15 Thus, the linear per kg dosing method seriously underestimates clearance in infants who are, therefore, often underdosed. This has been recently rediscovered in the treatment of life-threatening infection with malaria. [16] [17] [18] On the other hand, clearance is commonly reduced in neonates due to lack of maturation of elimination processes so the use of the linear per kg model may not be far from the right answer for this age group-but for the wrong reason.
| TH EORY-BASED ALLOMETRIC SCALING
Allometric scaling (Equation 2) has a long history of use in quantitative biology to describe the relationships between body size and structure and function. This equation forms the basis for allometric description and predictions of size-related pharmacokinetic parameters:
Y is the biological characteristic to be predicted, a is called the allometric coefficient, and b is the allometric exponent.
When the log of basal metabolic rate (BMR) is plotted against Figure 1 ). It can easily be seen that clearance per kg has its highest value around the age of 2 years although clearance as an absolute value continues to increase substantially until adulthood is reached. Maintenance dose rates calculated from these clearance per kg values will also be highest around the age of 2 years. This prediction is well known in pediatric anesthesia where a higher mg/kg propofol infusion rate is required in infants when compared with older children and adults. [24] [25] [26] Thus, this empirical observation of higher doses per kg in young children is predictable directly from fundamental biological concepts of growth associated with size and maturation.
| WHY TH EORY-BASED ALLOMETRY IS BETTER THAN BODY SURFACE AREA FOR SCALING BODY SIZE DIFFERENCES
Body surface area has been widely used to describe the relationship of size with function, eg, glomerular filtration rate (GFR), cardiac output, and drug metabolism. None of these functions are connected directly to the skin or its surface area so how did this happen? Sarrus and Rameaux (1839) put forward the theory that the rate of heat production in animals is in proportion to body surface area (BSA).
This is not unreasonable because a large part of heat loss from the body is dependent on the skin, and thus, heat loss might be expected to be related to BSA.
Body surface area is commonly predicted as a function of both height and weight. Meeh 27 proposed a function of weight using a theory-derived allometric exponent of 2/3 (Equation 3):
BSA was proposed in 1950 to be a more satisfactory index of drug requirements than a linear function of body weight or age, particularly during infancy and childhood. 28 The simplicity of the allometric 2/3 surface area law as an explanation proved so attractive that over a century of science was distorted by trying to fit observations to this model. Quantitative biologists have explored in great detail the relationship between BSA, body mass, and BMR across a wide range of species and sizes.
Direct tests of the allometric hypothesis based on the observed empirical relationship between metabolic rate and weight support the theoretical scaling exponent of 3/4 rather than 2/3.
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The use of allometry is not limited to prediction of metabolic rate but is applicable to all functional and structural aspects of biology including pharmacokinetic processes such as elimination and distribution. Prediction of measurements of GFR from very premature neonates to young adults showed BSA was markedly inferior to theory-based allometry with a weight exponent of 3/4. 30 It has been demonstrated that cardiac output 31, 32 and oxygen consumption (physiological functions related to BMR) 20 are better scaled with an allometric exponent closer to 3/4 than with BSA. Liver volume has been predicted with an empirical exponent of 0.78 from neonates to adults with no additional influence of age. 33 Kidney volume scales with an empirical exponent of 0.8. 34 In this respect, the volume of both liver and kidneys of neonates and infants reflect that they are just small adults. These empirical exponents support the use of theory-based allometry used 3/4 rather than 2/3 to predict the effect of size on hepatic drug metabolism and renal elimination independently from age-related maturation in the first 2 years of life. Although the BSAderived allometric exponent (2/3) closely approximates that based on allometric theory (3/4), we prefer to use a stronger theory linked to structure and function rather than BSA which has no mechanistic association with drug disposition. While the quantitative differences in predictions using 2/3 or 3/4 are not major, it is similar to assuming that the earth is a perfect sphere rather than an oblate spheroid. Why use the wrong answer if a better one is available? 6 | ME CH ANISMS FOR ALTERED
PHARMACOKINETICS IN OBESITY INDEPENDENT OF BOD Y SIZE
Although body fat has minimal metabolic activity, fat mass may have an indirect influence on both metabolic and renal function independent of its effects due to increased body mass. Because obesity is associated with other morbidity an effect independent of body size due to concurrent morbidity may influence body function. When there is no clear marker of morbidity, the effects of morbidity may appear as differences in pharmacokinetic parameters. This is a form of model misspecification that can only be detected when independent markers of morbidity are available.
The volume of distribution of a drug may depend on its physicochemical properties. There are drugs whose apparent volume of distribution may be independent of fat mass (eg, digoxin based on similar volumes in obese and nonobese subjects 35 and the lack of change in disposition associated with weight loss in obese subjects) 36 or be extensively associated with it (eg, benzodiazepines such as diazepam [37] [38] [39] ). It has been proposed that the larger volume of distribution of diazepam in obesity is due to its fat solubility, 37 but the finding of lower diazepam binding inhibitor in obese 
This formula is not directly applicable in children as a measure to define degrees of obesity. Weight does not increase linearly with age 42 (Figure 3 ) or height. BMI in children must be interpreted with reference to age and sex. A BMI of 20 kg m 2 in a young adult implies leanness; the same BMI in a 5-year-old child suggests a degree of obesity. 43 Charts are available that serve as references for BMIfor-age. 44 These aspects and their impact on pediatric anesthesia have been reviewed by Mortensen and colleagues. 7 BMI may be used as an indication of obesity but is also uncommonly used to predict dose in children because it fails to distinguish between adipose tissue and lean muscle mass. However, there are computer-based calculators available 
F I G U R E 3
The relationship between age and weight. The panel on the left shows raw data (n = 35446), while the right panel show a VPC with 5th, 50th, and 90th observed (dot-dash gray line) and predicted (dashed black line) percentiles and 95% confidence bands for predictions (gray shading) (data from Sumpter et al 42 with permission)
for dosing some drugs (eg, acetaminophen) based on BMI (eg, http:// www.bpac.org.nz/resources/other/bmi_calc/bmicalc.html)
| Pharmacokinetic mass
Adult fentanyl PK models were derived from normal weight patients (eg, ref. 45, 46) . These models were not scaled to body weight and their consequent application to obese patients may cause overprediction of the plasma concentration of fentanyl, a popular opioid used in anesthesia. 47 This concept is demonstrated in Figure 2 where allometry was used as a size scaler for propofol. Analysis of the difference between that fentanyl concentration predicted by the per kilogram linear model and the measured fentanyl concentration was used to develop a new mass that could be used for dosing; the "pharmacokinetic mass." The pharmacokinetic mass vs TBM curve was essentially linear below 100 kg (with slope of 0.65) and approached a plateau above 140 kg. 47 We note that "pharmacokinetic mass" bears a curvilinear relationship with TBW as might be expected from other more robust theorems (eg, allometric theory) ( Figure 4 ). 52 rocuronium, 53, 54 and cisatracurium 55 
| Lean body mass
It has been claimed that lean body mass (LBM) is the optimal size scalar for most drugs used in anesthesia including opioids and anesthetic induction agents. 7, [56] [57] [58] This argument has also been put forward for drugs used outside of anesthesia with the explicit assumption that clearance is linearly related to LBM. The use of lean body mass that assumes a linear assumption over the mass range appears a good predictor of dose for remifentanil, where 12 obese (weight 113 SD 17 kg) and 12 lean (weight 64 SD 10 kg) adults were studied. It is also believed to be better than TBM for both propofol infusion and induction dose calculation 59 in adults. However, other metrics of size were not explored in those studies. The merits of using LBM have been reviewed with the conclusion that LBM is a better predictor of drug dosage for all drugs. 60 The extension to all drugs remains unproven. 
These formulae have been used to create nomograms enabling determination of the ideal body mass (IBM) and LBM in children. 49 It has been assumed that clearance is linearly related to LBM. 1 However, it has been shown that a nonlinear function using allometric scaling is better when a wide range of masses is considered. 30, 61 Simplified calculations also exist for the estimate of LBM based on the observation that a mean of 29% of the excess weight carried by an obese child is lean tissue. 7, 62, 63 This can be expressed as fol-
lows (Equation 10):
F I G U R E 4 Body size metrics used to describe clearance relative to 70 kg TBM after maturation is complete. Metrics are based on a male with typical height for age and TBM from 10 to 200 kg. A nonlinear relationship exists between weight and clearance and the use of the linear model based on TBM increasingly overestimates clearance in adults of weight greater than 70 kg. The linear model underestimates clearance in children, while the BSA model overestimates clearance in children. The other descriptors are in close agreement between 45 and 100 kg. The use of BSA and allometry using an exponent of 3/4 are similar at lower masses but diverge when TBM is greater than 100 kg. Height is occasionally used as a size metric (eg, IBM [50] ), but its shape is very different from the other metrics for clearance 
into many common infusion pumps used for intravenous anesthesia in adults are inconsistent at extremes of size, particularly in those adults of short stature where a reduction of LBM is predicted as TBM increases. 65, 66 Methods used to circumvent this problem in pumps used for adults include calculation of a fictitious height 67 or by placing limits on maximum programmable weight allowed. 66 
| Fat-free mass
An alternative size metric to LBM is fat-free mass (FFM). FFM comprises muscle, bone vital organs, and extracellular fluid. LBM in addition includes lipid in CNS, bone marrow, and cell membranes. 68, 69 This lipid comprises less than 3%-5% of TBM, and consequently, FFM is often used interchangeably with LBM in clinical practice.
FFM can be measured using dual-energy X-ray absorbtiometry (the The extrapolation of the FFM formula developed in adults (Equation 13) has been described for children as young as 3 years. 72 This work suggests that girls have a FFM similar to that predicted from adults based on height, weight, and sex. Boys have lower than predicted FFM until around the onset of puberty and approach adult predictions in early adulthood.
Size is often described using total body weight but adjustment for body composition with FFM can improve predictions of GFR and drug clearance. 1 Remifentanil clearance increases with fat-free mass; 73 a metric that describes size similar to that of LBM. The importance of accounting for fat-free mass as well as total body weight has been demonstrated for busulfan in a large study of children and adults. That study showed that empirical estimates of allometric exponents are consistent with allometric theory. 61 FFM, LBM, and IBM formulae describe a curvilinear relationship (Figure 4 ), similar in shape to that observed using theory-based allometry ( Figure 4 ). Propofol clearance in obese children 74 and adults 11 and nonobese adults and children 12, 75, 76 is best predicted with theory-based allometry using TBM as the size descriptor rather than FFM, LBM, or IBM. 
